Market Cap 38.46B
Revenue (ttm) 3.71B
Net Income (ttm) 313.75M
EPS (ttm) N/A
PE Ratio 81.85
Forward PE 40.96
Profit Margin 8.45%
Debt to Equity Ratio 0.00
Volume 1,280,836
Avg Vol 1,278,236
Day's Range N/A - N/A
Shares Out 133.51M
Stochastic %K 2%
Beta 0.27
Analysts Strong Sell
Price Target $439.12

Company Profile

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products i...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 551 8200
Fax: 617 551 8101
Address:
675 West Kendall Street, Henri A. Termeer Square, Cambridge, United States
ChromeOnTheWheels
ChromeOnTheWheels Jul. 15 at 8:14 PM
$ALNY $KTOS Positions open this week. $BBW Position closed this week.
0 · Reply
sampeper
sampeper Jul. 15 at 3:50 PM
$ALNY HC Wainwright Has Positive Estimate for ALNY FY2028 Earnings HC Wainwright raised its FY2028 EPS estimate for Alnylam Pharmaceuticals to $12.46 from $12.15 and kept a Buy rating with a $485 price target. The firm also projected FY2029 EPS of $16.28 and FY2030 EPS of $20.67. https://www.marketbeat.com/instant-alerts/hc-wainwright-has-positive-estimate-for-alny-fy2028-earnings-2026-07-15/
0 · Reply
sampeper
sampeper Jul. 15 at 11:30 AM
$ALNY Alnylam Initiates Mid-Stage Study of Mivelsiran in Down Syndrome-Associated Alzheimer's https://www.marketscreener.com/news/alnylam-initiates-mid-stage-study-of-mivelsiran-in-down-syndrome-associated-alzheimer-s-ce7f5eddd08df421
0 · Reply
sampeper
sampeper Jul. 15 at 10:15 AM
$ALNY Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease https://www.businesswire.com/news/home/20260715865310/en/Alnylam-Highlights-Progress-with-Neuroscience-Programs-at-AAIC-2026-Showcasing-Potential-of-RNAi-in-Neurological-Disease
0 · Reply
sampeper
sampeper Jul. 15 at 10:10 AM
$ALNY Alnylam advances Alzheimer's drug trials, reports mivelsiran safety data https://www.streetinsider.com/dr/news.php?id=26769975&gfv=1
0 · Reply
sampeper
sampeper Jul. 15 at 9:32 AM
$ALNY Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease https://www.stocktitan.net/news/ALNY/alnylam-highlights-progress-with-neuroscience-programs-at-aaic-2026-qxkovq0tx9e3.html
0 · Reply
sampeper
sampeper Jul. 15 at 9:31 AM
$ALNY Stifel Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $444 https://www.moomoo.com/news/post/72945864/stifel-maintains-alnylam-pharmaceuticals-alnyus-with-buy-rating-maintains-target?level=1&data_ticket=1776416983151450
0 · Reply
sampeper
sampeper Jul. 15 at 9:31 AM
$ALNY Morgan Stanley Raises its Price Target on Alnylam (ALNY) https://finance.yahoo.com/markets/stocks/articles/morgan-stanley-raises-price-target-160956965.html
0 · Reply
sampeper
sampeper Jul. 15 at 9:29 AM
$ALNY Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease https://uk.finance.yahoo.com/news/alnylam-highlights-progress-neuroscience-programs-073000834.html
0 · Reply
dogDazeSummer
dogDazeSummer Jul. 14 at 1:57 PM
$IFRX Welcome Fidelity Sector Fund. The first real mutual fund for our German baby in a long time. Now w funding risk removed in “shoe in for AAV” (given Amgen sketchiness. EMA / FDA clearly seek retribution). And the first major Biotech *mutual fund* takes a 3.2m share starter. Follow the leaders. This Fidelity fund holds about 114 positions Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund 3.2M shares Inflarx. May 31, 2026 4.42% 6,392,142 26 year old fund FY July, +22% YTD; +77% TTM; 10% over 10 years. 159 Holdings Inflarx is now just 1 of 6 international holdings. Obviously a special situation and wisely bought on pullbacks 5 Star Mormingside Fund in all categories Profile: Eirene Kontopoulos Since 07/14/2018 B.S., Haverford College, 2002 PhD, Harvard University - Harvard Medical School, 2007 Top Holdings: $ABBV $GILD $BIIB $ALNY https://institutional.fidelity.com/app/funds-and-products/116/fidelity-advisor-biotechnology-fund-class-i-fbtix.html
1 · Reply
Latest News on ALNY
Alnylam price target lowered to $410 from $460 at BofA

2026-07-14T12:21:04.000Z - 1 day ago

Alnylam price target lowered to $410 from $460 at BofA


Alnylam price target lowered to $410 from $505 at Truist

2026-07-13T13:55:42.000Z - 2 days ago

Alnylam price target lowered to $410 from $505 at Truist


Alnylam Pharmaceuticals Transcript: Study update

Jun 25, 2026, 11:00 AM EDT - 20 days ago

Alnylam Pharmaceuticals Transcript: Study update


Alnylam Pharmaceuticals Slides: Study update

Jun 25, 2026, 11:00 AM EDT - 20 days ago

Alnylam Pharmaceuticals Slides: Study update


Komodo expands strategic partnership with Alnylam

2026-06-25T13:20:16.000Z - 20 days ago

Komodo expands strategic partnership with Alnylam


The Healthcare M&A Wave

Jun 17, 2026, 12:30 PM EDT - 4 weeks ago

The Healthcare M&A Wave

ABT AMGN AMRX ANTX AZN BDX BEAM


Alnylam to Host Tenth “RNAi Roundtable” Webcast Series

Jun 12, 2026, 9:00 AM EDT - 4 weeks ago

Alnylam to Host Tenth “RNAi Roundtable” Webcast Series


Alnylam, GENESIS Pharma expand commercial partnership

2026-06-10T11:50:10.000Z - 5 weeks ago

Alnylam, GENESIS Pharma expand commercial partnership


Alnylam, Inceptive form strategic AI collaboration

2026-06-03T20:50:11.000Z - 6 weeks ago

Alnylam, Inceptive form strategic AI collaboration


Alnylam Pharmaceuticals Transcript: AGM 2026

May 20, 2026, 10:30 AM EDT - 2 months ago

Alnylam Pharmaceuticals Transcript: AGM 2026


Alnylam Issues 2025 Corporate Responsibility Report

May 19, 2026, 8:30 AM EDT - 2 months ago

Alnylam Issues 2025 Corporate Responsibility Report


Alnylam initiated with a Buy at Citi

2026-05-18T20:25:59.000Z - 2 months ago

Alnylam initiated with a Buy at Citi


Alnylam price target raised to $370 from $360 at Morgan Stanley

2026-05-01T15:51:39.000Z - 2 months ago

Alnylam price target raised to $370 from $360 at Morgan Stanley


Alnylam price target lowered to $447 from $448 at Bernstein

2026-05-01T14:21:06.000Z - 2 months ago

Alnylam price target lowered to $447 from $448 at Bernstein


Alnylam reports Q1 EPS $1.99, consensus $1.47

2026-04-30T16:59:31.000Z - 2 months ago

Alnylam reports Q1 EPS $1.99, consensus $1.47


Alnylam Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 2 months ago

Alnylam Pharmaceuticals Earnings Call Transcript: Q1 2026


Alnylam Pharmaceuticals Quarterly report: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 2 months ago

Alnylam Pharmaceuticals Quarterly report: Q1 2026


Alnylam Pharmaceuticals Slides: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 2 months ago

Alnylam Pharmaceuticals Slides: Q1 2026


Alnylam Pharmaceuticals Earnings release: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 2 months ago

Alnylam Pharmaceuticals Earnings release: Q1 2026


Alnylam Pharmaceuticals Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 3 months ago

Alnylam Pharmaceuticals Proxy statement: Proxy filing


Alnylam Pharmaceuticals Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 3 months ago

Alnylam Pharmaceuticals Proxy statement: Proxy filing


Alnylam Pharmaceuticals Transcript: Status update

Mar 24, 2026, 9:30 AM EDT - 4 months ago

Alnylam Pharmaceuticals Transcript: Status update


Alnylam Pharmaceuticals Press release: Status update

Mar 24, 2026, 9:30 AM EDT - 4 months ago

Alnylam Pharmaceuticals Press release: Status update


Alnylam Pharmaceuticals Slides: Status update

Mar 24, 2026, 9:30 AM EDT - 4 months ago

Alnylam Pharmaceuticals Slides: Status update


How Alnylam Stock Weathers Market Shocks

Mar 11, 2026, 11:55 AM EDT - 4 months ago

How Alnylam Stock Weathers Market Shocks


Alnylam to Webcast TTR Investor Webinar

Mar 10, 2026, 8:00 AM EDT - 4 months ago

Alnylam to Webcast TTR Investor Webinar


Alnylam Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 12, 2026, 8:30 AM EST - 5 months ago

Alnylam Pharmaceuticals Earnings Call Transcript: Q4 2025


Alnylam Pharmaceuticals Annual report: Q4 2025

Feb 12, 2026, 8:30 AM EST - 5 months ago

Alnylam Pharmaceuticals Annual report: Q4 2025


Alnylam Pharmaceuticals Earnings release: Q4 2025

Feb 12, 2026, 8:30 AM EST - 5 months ago

Alnylam Pharmaceuticals Earnings release: Q4 2025


Alnylam Pharmaceuticals Slides: Q4 2025

Feb 12, 2026, 8:30 AM EST - 5 months ago

Alnylam Pharmaceuticals Slides: Q4 2025


Alnylam Pharmaceuticals Annual report: Q4 2025

Feb 12, 2026, 8:30 AM EST - 5 months ago

Alnylam Pharmaceuticals Annual report: Q4 2025


Alnylam Pharmaceuticals Announces Changes to Board of Directors

Dec 3, 2025, 8:00 AM EST - 8 months ago

Alnylam Pharmaceuticals Announces Changes to Board of Directors


UK's drug-cost watchdog recommends Alnylam's heart disease drug

Nov 20, 2025, 7:09 PM EST - 8 months ago

UK's drug-cost watchdog recommends Alnylam's heart disease drug


Alnylam Pharmaceuticals Earnings Call Transcript: Q3 2025

Oct 30, 2025, 8:30 AM EDT - 9 months ago

Alnylam Pharmaceuticals Earnings Call Transcript: Q3 2025


Alnylam Pharmaceuticals Quarterly report: Q3 2025

Oct 30, 2025, 8:30 AM EDT - 9 months ago

Alnylam Pharmaceuticals Quarterly report: Q3 2025


Alnylam Pharmaceuticals Earnings release: Q3 2025

Oct 30, 2025, 8:30 AM EDT - 9 months ago

Alnylam Pharmaceuticals Earnings release: Q3 2025


Alnylam Pharmaceuticals Slides: Q3 2025

Oct 30, 2025, 8:30 AM EDT - 9 months ago

Alnylam Pharmaceuticals Slides: Q3 2025


Alnylam Pharmaceuticals Transcript: Status Update

Aug 30, 2025, 1:00 PM EDT - 11 months ago

Alnylam Pharmaceuticals Transcript: Status Update


Alnylam Pharmaceuticals Slides: Status Update

Aug 30, 2025, 1:00 PM EDT - 11 months ago

Alnylam Pharmaceuticals Slides: Status Update


ChromeOnTheWheels
ChromeOnTheWheels Jul. 15 at 8:14 PM
$ALNY $KTOS Positions open this week. $BBW Position closed this week.
0 · Reply
sampeper
sampeper Jul. 15 at 3:50 PM
$ALNY HC Wainwright Has Positive Estimate for ALNY FY2028 Earnings HC Wainwright raised its FY2028 EPS estimate for Alnylam Pharmaceuticals to $12.46 from $12.15 and kept a Buy rating with a $485 price target. The firm also projected FY2029 EPS of $16.28 and FY2030 EPS of $20.67. https://www.marketbeat.com/instant-alerts/hc-wainwright-has-positive-estimate-for-alny-fy2028-earnings-2026-07-15/
0 · Reply
sampeper
sampeper Jul. 15 at 11:30 AM
$ALNY Alnylam Initiates Mid-Stage Study of Mivelsiran in Down Syndrome-Associated Alzheimer's https://www.marketscreener.com/news/alnylam-initiates-mid-stage-study-of-mivelsiran-in-down-syndrome-associated-alzheimer-s-ce7f5eddd08df421
0 · Reply
sampeper
sampeper Jul. 15 at 10:15 AM
$ALNY Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease https://www.businesswire.com/news/home/20260715865310/en/Alnylam-Highlights-Progress-with-Neuroscience-Programs-at-AAIC-2026-Showcasing-Potential-of-RNAi-in-Neurological-Disease
0 · Reply
sampeper
sampeper Jul. 15 at 10:10 AM
$ALNY Alnylam advances Alzheimer's drug trials, reports mivelsiran safety data https://www.streetinsider.com/dr/news.php?id=26769975&gfv=1
0 · Reply
sampeper
sampeper Jul. 15 at 9:32 AM
$ALNY Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease https://www.stocktitan.net/news/ALNY/alnylam-highlights-progress-with-neuroscience-programs-at-aaic-2026-qxkovq0tx9e3.html
0 · Reply
sampeper
sampeper Jul. 15 at 9:31 AM
$ALNY Stifel Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $444 https://www.moomoo.com/news/post/72945864/stifel-maintains-alnylam-pharmaceuticals-alnyus-with-buy-rating-maintains-target?level=1&data_ticket=1776416983151450
0 · Reply
sampeper
sampeper Jul. 15 at 9:31 AM
$ALNY Morgan Stanley Raises its Price Target on Alnylam (ALNY) https://finance.yahoo.com/markets/stocks/articles/morgan-stanley-raises-price-target-160956965.html
0 · Reply
sampeper
sampeper Jul. 15 at 9:29 AM
$ALNY Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease https://uk.finance.yahoo.com/news/alnylam-highlights-progress-neuroscience-programs-073000834.html
0 · Reply
dogDazeSummer
dogDazeSummer Jul. 14 at 1:57 PM
$IFRX Welcome Fidelity Sector Fund. The first real mutual fund for our German baby in a long time. Now w funding risk removed in “shoe in for AAV” (given Amgen sketchiness. EMA / FDA clearly seek retribution). And the first major Biotech *mutual fund* takes a 3.2m share starter. Follow the leaders. This Fidelity fund holds about 114 positions Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund 3.2M shares Inflarx. May 31, 2026 4.42% 6,392,142 26 year old fund FY July, +22% YTD; +77% TTM; 10% over 10 years. 159 Holdings Inflarx is now just 1 of 6 international holdings. Obviously a special situation and wisely bought on pullbacks 5 Star Mormingside Fund in all categories Profile: Eirene Kontopoulos Since 07/14/2018 B.S., Haverford College, 2002 PhD, Harvard University - Harvard Medical School, 2007 Top Holdings: $ABBV $GILD $BIIB $ALNY https://institutional.fidelity.com/app/funds-and-products/116/fidelity-advisor-biotechnology-fund-class-i-fbtix.html
1 · Reply
sampeper
sampeper Jul. 13 at 4:48 PM
$ALNY q2 and q3 earnings will be spectacular, outperform $650
1 · Reply
sampeper
sampeper Jul. 13 at 4:47 PM
$ALNY Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $485.00 at HC Wainwright https://www.marketbeat.com/instant-alerts/alnylam-pharmaceuticals-nasdaqalny-price-target-raised-to-48500-at-hc-wainwright-2026-07-13/
0 · Reply
CDMO
CDMO Jul. 13 at 4:12 PM
$ALNY lol wtf happened here. Thought it will recover after ions news. Still no position again
0 · Reply
sampeper
sampeper Jul. 13 at 3:44 PM
$ALNY mega short sequence will start any time 🫠 🫠 🫠
0 · Reply
akinyo
akinyo Jul. 13 at 3:28 PM
$ALNY unbelievable..
0 · Reply
sampeper
sampeper Jul. 13 at 3:27 PM
$ALNY Raymond James Adjusts Price Target on Alnylam Pharmaceuticals to $468 From $420, Maintains Outperform Rating https://www.marketscreener.com/news/raymond-james-adjusts-price-target-on-alnylam-pharmaceuticals-to-468-from-420-maintains-outperfor-ce7f5ededb80fe22
0 · Reply
sampeper
sampeper Jul. 13 at 3:25 PM
$ALNY breaking news: Alnylam price target raised to $485 from $470 at H.C. Wainwright https://www.tipranks.com/news/the-fly/alnylam-price-target-raised-to-485-from-470-at-h-c-wainwright-thefly-news
0 · Reply
sampeper
sampeper Jul. 13 at 3:19 PM
$ALNY add 😗😗😗
0 · Reply
Arcides
Arcides Jul. 13 at 2:44 PM
$ALNY que horrible machucada....
0 · Reply
WAJeff
WAJeff Jul. 13 at 2:43 PM
$ALNY add 286.26
0 · Reply
Wallstfan
Wallstfan Jul. 13 at 2:18 PM
$ALNY added at $280. Thanks for the discount
0 · Reply
BioTechHealthX
BioTechHealthX Jul. 12 at 12:27 AM
$ALNY Alnylam Pharmaceuticals (NASDAQ: ALNY) isn't your typical biotech company. With its revolutionary RNAi platform targeting diseases at the genetic level, investors are wondering if ALNY could be one of the smartest biotech stocks to own. Here's what makes this company stand out from the competition. https://biotechhealthx.com/biotech-news/could-alnylam-pharma-alny-be-a-smart-long-term-bet-on-rna-therapies/
0 · Reply